Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733735 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL19663806 | 0.93 | CHRNB2 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL14095920 | 0.93 | CHRNB2 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL16316906 | 0.93 | SLC18A3 (0.39) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL16316905 | 0.89 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL19013814 | 0.86 | — | — | |
| SCHEMBL21883665 | 0.86 | — | — | |
| SCHEMBL4757755 | 0.86 | — | — | |
| SCHEMBL16316907 | 0.86 | CHRNB2 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL16273339 | 0.81 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-05 | — | — | US | claimed |
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | US | claimed |
| US-6291452-B1 | CHOLECYSTOKININ ANTAGONISTS. | FUJISAWA PHARMACETICAL CO., LTD. (JP) | 2001-09-18 | — | — | US | claimed |
| US-12037447-B2 | Systems and processes for polymer production | NOVOMER, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3250209-B1 | COMT INHIBITING METHODS AND COMPOSITIONS | LIEBER INST FOR BRAIN DEVELOPMENT (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20220251018-A1 | PRODUCTION SYSTEM/PRODUCTION PROCESS FOR ACRYLIC ACID AND PRECURSORS THEREOF | NOVOMER, INC. | 2022-08-11 | — | — | US | disclosed |
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2022-05-31 | — | — | US | disclosed |
| US-11185853-B2 | Catalysts for polycarbonate production | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2021-11-30 | — | — | US | disclosed |
| US-11155511-B2 | Distillation process for production of acrylic acid | NOVOMER, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210108010-A1 | SYSTEMS AND PROCESSES FOR POLYACRYLIC ACID PRODUCTION | NOVOMER, INC. | 2021-04-15 | — | — | US | disclosed |
| US-20200384114-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2020-12-10 | — | — | US | disclosed |
| US-20080096901-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2008-04-24 | — | — | US | disclosed |
| WO-2008031550-A2 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTANATE RECEPTORS | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007071358-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-7173033-B2 | Nitrogen-containing heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7173033-B2 | Nitrogen-containing heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-05 | — | — | US | disclosed |
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | US | disclosed |
| US-6291452-B1 | CHOLECYSTOKININ ANTAGONISTS. | FUJISAWA PHARMACETICAL CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | CHRNB2 387/4885CHRNB4 599/4885CHRNA3 1056/4885 |
| US-20220251018-A1 | PRODUCTION SYSTEM/PRODUCTION PROCESS FOR ACRYLIC ACID AND PRECURSORS THEREOF | COASY, ALAD, PCCA | CHRNB2 2935/4885CHRNB4 3211/4885CHRNA3 2828/4885 |
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | CHRNB2 295/4885CHRNB4 201/4885CHRNA3 153/4885 |
| US-20210108010-A1 | SYSTEMS AND PROCESSES FOR POLYACRYLIC ACID PRODUCTION | ACSL3, BPHL, ADSL | CHRNB2 2605/4885CHRNB4 2450/4885CHRNA3 3465/4885 |
| US-11155511-B2 | Distillation process for production of acrylic acid | ALAD, PCCA, ADSL | CHRNB2 3061/4885CHRNB4 3221/4885CHRNA3 2898/4885 |
| US-20200384114-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | CCKBR, CCKAR, GRPR | CHRNB2 387/4885CHRNB4 599/4885CHRNA3 1056/4885 |
| US-20080096901-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | MAP3K20, MAP3K5, MAP3K1 | CHRNB2 4538/4885CHRNB4 4746/4885CHRNA3 4163/4885 |
| US-12037447-B2 | Systems and processes for polymer production | PGLS, APC, PHYKPL | CHRNB2 3533/4885CHRNB4 3406/4885CHRNA3 3842/4885 |
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | CHRNB2 295/4885CHRNB4 201/4885CHRNA3 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.